ArticleScience (New York, N.Y.)2024
Engineering synthetic suppressor T cells that execute locally targeted immunoprotective programs.
Abstract read
In one paragraph
Article in Science (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Article
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
- Next-generation programmable cell therapies for precision medicine.Nature reviews. Genetics · 2026Review
- TRACR: an anterograde transneuronal tracing system for genetic access across synapses and longitudinal circuit analysis.bioRxiv : the preprint server for biology · 2026Article
- Precision Immunoregulation in transplantation: The rise of engineered Treg therapies.Molecular biology reports · 2026Review
- Progress in the development of cytokine armoured CAR T cells.Nature reviews. Immunology · 2026Review
- Enhancing persistence while managing cytokine release syndrome to embrace next-generation CAR-T cell therapy.Journal of translational medicine · 2026Review
- Cytokine-Engineered Chimeric Antigen Receptor-T Cell Therapy: How to Balance the Efficacy and Toxicity.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Programmable nanobody circuits for cell selection.bioRxiv : the preprint server for biology · 2026Article
- Emerging roles of Notch signaling in the tumor microenvironment of digestive system cancers.Frontiers in molecular biosciences · 2026Review
- Regulatory T cells in autoimmune diseases: biological mechanisms, clinical translation, and translational challenges.Frontiers in immunology · 2026Review
- Translational potential of γδ T cells in hematologic diseases: from immunobiology to therapeutic innovation.Frontiers in immunology · 2026Review
- Integrating synthetic biology to understand and engineer the heart, lung, blood, and sleep systems.Cell systems · 2025Review
- Immunoevasion strategies for African swine fever virus: Modulation of antigen presentation pathways.Virulence · 2025Review
- Cellular Therapies in Transplantation - Regulatory T Cell Therapies and Virus Specific Therapies.Current transplantation reports · 2025Article
- CAR T Cell Therapy for Rheumatoid Arthritis.Clinical reviews in allergy & immunology · 2025Review
- Cell Fate Determination and Lineage Tracing: Technological Evolution and Multidimensional Applications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- The Rise of Mechanobiology for Advanced Cell Engineering and Manufacturing.Advanced materials (Deerfield Beach, Fla.) · 2025Review
- Causes of symptoms and symptom persistence in long COVID and myalgic encephalomyelitis/chronic fatigue syndrome.Cell reports. Medicine · 2025Review
- Organoid models in oncology: advancing precision cancer therapy and vaccine development.Cancer biology & medicine · 2025Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
14 authors.
Nishith R ReddyUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5912-6925
Hasna MaachiDiabetes Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0002-3044-2582
Yini XiaoUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0007-5108-7301
Milos S SimicUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1167-0857
Wei YuUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3154-5084
Yurie TonaiUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-9610-6667
Daniela A CabanillasUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1321-9656
Ella Serrano-WuUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0009-0003-1666-1778
Philip T PauersteinUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0001-5157-204X
Whitney TamakiUCSF CoLabs, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-1124-628X
Greg M AllenUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-0032-8140
Audrey V ParentDiabetes Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4506-6268
Matthias HebrokDiabetes Center, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0002-3833-8862
Wendell A LimUCSF Cell Design Institute, University of California, San Francisco, San Francisco, CA, USA.ORCID 0000-0003-4052-8056
Funding
Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8MUser-control and safetyU54CA244438 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2019 to 2022
$7.8MResearch Training in Childhood CancerT32CA128583 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Eric Alejandro Sweet-Cordero · 2007 to 2026
$6.0MDesigner Tregs for restoring tolerance in patients with type 1 diabetesUC4DK116264 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLUESTONE, JEFFREY A, LIM, WENDELL A · 2017 to 2017
$3.4MEngineering synthetic immune cells with modular sentinel and therapeutic functions for T1DR01DK132547 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LIM, WENDELL A · 2022 to 2025
$3.3MAmeliorating off-target toxicities of CAR T cells by engineering NOT gatesR01CA258789 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WENDELL A LIM · 2022 to 2026
$2.2MNCI NIH HHS R01 CA258789NCI NIH HHS T32 CA128583NCI NIH HHS U54 CA244438NIDDK NIH HHS P30 DK063720NIDDK NIH HHS R01 DK132547NIDDK NIH HHS UC4 DK116264
Abstract
Immune homeostasis requires a balance of inflammatory and suppressive activities. To design cells potentially useful for local immune suppression, we engineered conventional CD4
Indexed as
CD4-Positive T-LymphocytesCell EngineeringImmunosuppression TherapyReceptors, Chimeric AntigenAnimalsB7-H1 AntigenBystander EffectCross ReactionsHumansInterleukin-10MiceMice, Inbred C57BLOrganoidsReceptors, NotchT-Lymphocytes, CytotoxicTransforming Growth Factor beta1B7-H1 AntigenInterleukin-10Receptors, Chimeric AntigenReceptors, NotchTransforming Growth Factor beta1
Identifiers
What Socratic holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.